MA41850A - Nouvelles utilisations pharmaceutiques - Google Patents

Nouvelles utilisations pharmaceutiques

Info

Publication number
MA41850A
MA41850A MA041850A MA41850A MA41850A MA 41850 A MA41850 A MA 41850A MA 041850 A MA041850 A MA 041850A MA 41850 A MA41850 A MA 41850A MA 41850 A MA41850 A MA 41850A
Authority
MA
Morocco
Prior art keywords
new pharmaceutical
pharmaceutical uses
new
pharmaceutical
Prior art date
Application number
MA041850A
Other languages
English (en)
Inventor
Mark Hibberd
Richard Jenkins
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41850(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1505526.2A external-priority patent/GB201505526D0/en
Priority claimed from GBGB1521015.6A external-priority patent/GB201521015D0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA41850A publication Critical patent/MA41850A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA041850A 2015-03-31 2016-03-29 Nouvelles utilisations pharmaceutiques MA41850A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1505526.2A GB201505526D0 (en) 2015-03-31 2015-03-31 Novel pharmaceutical uses
GBGB1521015.6A GB201521015D0 (en) 2015-11-27 2015-11-27 Novel pharmaceutical uses

Publications (1)

Publication Number Publication Date
MA41850A true MA41850A (fr) 2018-02-06

Family

ID=55806738

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041850A MA41850A (fr) 2015-03-31 2016-03-29 Nouvelles utilisations pharmaceutiques

Country Status (22)

Country Link
US (2) US20180085361A1 (fr)
EP (1) EP3277279A1 (fr)
JP (1) JP2018513140A (fr)
KR (1) KR20170132260A (fr)
CN (1) CN107530335A (fr)
AU (1) AU2016241069A1 (fr)
BR (1) BR112017021024A2 (fr)
CA (1) CA2981244A1 (fr)
CL (1) CL2017002325A1 (fr)
CO (1) CO2017010019A2 (fr)
CR (1) CR20170404A (fr)
DO (1) DOP2017000218A (fr)
EA (1) EA201792148A1 (fr)
EC (1) ECSP17072984A (fr)
IL (1) IL254419A0 (fr)
MA (1) MA41850A (fr)
MX (1) MX2017012414A (fr)
PE (1) PE20180195A1 (fr)
PH (1) PH12017501751A1 (fr)
SG (1) SG11201706739WA (fr)
TN (1) TN2017000416A1 (fr)
WO (1) WO2016159386A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3277685B1 (fr) 2015-03-31 2021-01-13 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
JP7228535B2 (ja) 2017-07-10 2023-02-24 武田薬品工業株式会社 ボノプラザン含有製剤
WO2024027549A1 (fr) * 2022-08-04 2024-02-08 江苏柯菲平医药股份有限公司 Composition pharmaceutique contenant un inhibiteur de sécrétion d'acide gastrique pyrrole et son procédé de préparation
CN116270443A (zh) * 2022-10-27 2023-06-23 广州白云山天心制药股份有限公司 富马酸伏诺拉生注射液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005280740B2 (en) 2004-09-03 2011-04-28 Yuhan Corporation Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
WO2008130863A2 (fr) * 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Benzimidazoles substitués
CA2936400C (fr) 2008-07-28 2018-03-27 Takeda Pharmaceutical Company Limited Composition pharmaceutique
WO2011004882A1 (fr) 2009-07-09 2011-01-13 ラクオリア創薬株式会社 Antagoniste de la pompe à acide destiné au traitement de maladies associées à un transit gastro-intestinal anormal
CN105143187B (zh) 2013-02-28 2018-04-03 武田药品工业株式会社 制备磺酰氯化合物的方法
CN103951652B (zh) * 2014-04-18 2015-09-23 潍坊博创国际生物医药研究院 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺水溶性有机酸盐和注射剂及它们的制备方法

Also Published As

Publication number Publication date
PH12017501751A1 (en) 2018-04-11
PE20180195A1 (es) 2018-01-26
DOP2017000218A (es) 2018-01-31
AU2016241069A1 (en) 2017-09-21
KR20170132260A (ko) 2017-12-01
CL2017002325A1 (es) 2017-12-29
CN107530335A (zh) 2018-01-02
JP2018513140A (ja) 2018-05-24
WO2016159386A1 (fr) 2016-10-06
IL254419A0 (en) 2017-11-30
CR20170404A (es) 2018-01-10
CA2981244A1 (fr) 2016-10-06
US20190070159A1 (en) 2019-03-07
EA201792148A1 (ru) 2018-02-28
CO2017010019A2 (es) 2018-02-20
ECSP17072984A (es) 2018-02-28
BR112017021024A2 (pt) 2018-07-03
US20180085361A1 (en) 2018-03-29
SG11201706739WA (en) 2017-09-28
TN2017000416A1 (en) 2019-01-16
MX2017012414A (es) 2018-01-26
EP3277279A1 (fr) 2018-02-07

Similar Documents

Publication Publication Date Title
DK3328880T3 (da) Terapeutiske midler
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
DK3188724T3 (da) Liposom-indkapslet affinitetsmedikament
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
DK3265421T3 (da) Doseringssystem
BR112016023628A2 (pt) composições farmacêuticas.
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
MA50541A (fr) Formulations pharmaceutiques
DK3259015T3 (da) Bioelektroniske lægemidler
BR112017027227A2 (pt) Agente anti-câncer
DK3529240T3 (da) Farmaceutiske forbindelser
MA42303A (fr) Formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
MA45187A (fr) Combinaisons pharmaceutiques
ES2841649T5 (es) Composición farmacéutica
MA49837A (fr) Compositions pharmaceutiques
DK3283058T3 (da) Ribociclib-tablet
MA41850A (fr) Nouvelles utilisations pharmaceutiques
KR20180084810A (ko) 정제 세트
DK3280447T3 (da) Farmaceutiske formuleringer
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes
FR3026399B1 (fr) Grue, notamment grue-derrick
DE112017002511A5 (de) Schaftfräser
DK3432887T3 (da) Anti-tuberkulosemiddel